ATE493148T1 - Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür - Google Patents

Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür

Info

Publication number
ATE493148T1
ATE493148T1 AT02793851T AT02793851T ATE493148T1 AT E493148 T1 ATE493148 T1 AT E493148T1 AT 02793851 T AT02793851 T AT 02793851T AT 02793851 T AT02793851 T AT 02793851T AT E493148 T1 ATE493148 T1 AT E493148T1
Authority
AT
Austria
Prior art keywords
antibodies
native human
bind
blood coagulation
binding
Prior art date
Application number
AT02793851T
Other languages
English (en)
Inventor
Jin-An Jiao
Hing Wong
Esperanza Nieves
Luis Mosquera
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/990,586 external-priority patent/US20030109680A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE493148T1 publication Critical patent/ATE493148T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02793851T 2001-10-29 2002-10-29 Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür ATE493148T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34330601P 2001-10-29 2001-10-29
US09/990,586 US20030109680A1 (en) 2001-11-21 2001-11-21 Antibodies for inhibiting blood coagulation and methods of use thereof
PCT/US2002/034727 WO2003037911A2 (en) 2001-10-29 2002-10-29 Antibodies for inhibiting blood coagulation and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE493148T1 true ATE493148T1 (de) 2011-01-15

Family

ID=26993414

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02793851T ATE493148T1 (de) 2001-10-29 2002-10-29 Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür

Country Status (11)

Country Link
EP (1) EP1446157B1 (de)
JP (1) JP4439914B2 (de)
KR (1) KR100951432B1 (de)
CN (1) CN100575364C (de)
AT (1) ATE493148T1 (de)
CA (1) CA2465325C (de)
DE (1) DE60238782D1 (de)
DK (1) DK1446157T3 (de)
HK (1) HK1068798A1 (de)
TW (1) TWI338009B (de)
WO (1) WO2003037911A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
CA2483909A1 (en) * 2002-05-01 2003-11-13 Schering Aktiengesellschaft Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
BRPI0410875A (pt) * 2003-05-30 2006-07-04 Centocor Inc método de inibição do crescimento de tumor com anticorpos de fator antitecido
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
ES2527102T3 (es) * 2003-06-19 2015-01-20 Genentech, Inc. Composiciones y métodos para el tratamiento de trastornos relacionados con la coagulación
EP1749536A1 (de) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Aktivierte Stimulatoren des Faktors X als antihämorrhagisches Mittel für die topische Anwendung
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2582728B1 (de) 2010-06-15 2017-08-23 Genmab A/S Menschliche antikörper-arzneimittelkonjugate gegen den gewebefaktor
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
BR112015023500B1 (pt) 2013-03-15 2021-01-12 The Regents Of The University Of California composição farmacêutica
KR20160136279A (ko) * 2014-02-03 2016-11-29 국립연구개발법인 고쿠리츠간켄큐센터 항-조직 인자 모노클로널 항체
SI3337817T1 (sl) * 2015-08-21 2021-12-31 F. Hoffmann - La Roche Ag Postopek za redukcijo beljakovin gostiteljske celice pri afinitetni kromatografiji
CN107446047B (zh) * 2017-09-04 2020-08-11 山西省生物研究院有限公司 一种双功能性抗组织因子人源化抗体及其制备方法
AU2019328290B2 (en) 2018-08-30 2024-10-10 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
SG11202101780WA (en) 2018-08-30 2021-03-30 Hcw Biologics Inc Single-chain chimeric polypeptides and uses thereof
CA3109139A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
CN114269903A (zh) 2019-06-21 2022-04-01 Hcw生物科技公司 多链嵌合多肽和其用途
CA3169625A1 (en) * 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ATE266726T1 (de) * 1995-06-07 2004-05-15 Ortho Pharma Corp CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
HUP0100813A3 (en) * 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
EP1263960A2 (de) * 2000-03-16 2002-12-11 Genentech, Inc. Antikörper gegen gewebefaktor (tf) mit erhöhter antikoagulierender wirkung

Also Published As

Publication number Publication date
WO2003037911A2 (en) 2003-05-08
WO2003037911A3 (en) 2003-12-31
CA2465325C (en) 2014-08-05
CN100575364C (zh) 2009-12-30
EP1446157B1 (de) 2010-12-29
DK1446157T3 (da) 2011-03-21
CN1599624A (zh) 2005-03-23
EP1446157A4 (de) 2005-12-28
DE60238782D1 (de) 2011-02-10
JP2006503541A (ja) 2006-02-02
KR100951432B1 (ko) 2010-04-07
CA2465325A1 (en) 2003-05-08
HK1068798A1 (en) 2005-05-06
TWI338009B (en) 2011-03-01
KR20050040844A (ko) 2005-05-03
EP1446157A2 (de) 2004-08-18
JP4439914B2 (ja) 2010-03-24

Similar Documents

Publication Publication Date Title
ATE493148T1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
ATE540976T1 (de) Antikörper zur inhibierung der blutgerinnung und verfahren zur deren verwendung
WO2010065077A3 (en) Antagonists of il-6 to prevent or treat thrombosis
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
RS102404A (sr) Nova antitela koja ciljaju tkivni faktor kao antikoagulanti
WO2005054273A3 (en) Humanized antibodies against vascular endothelial growth factor
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
WO2002060955A3 (en) Modified antibodies and methods of use
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
WO2011066374A3 (en) Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
WO2008063213A3 (en) Uses and compositions for treatment of psoriatic arthritis
WO2006110214A3 (en) Antibodies against mammalian metapneumovirus
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
DK1194528T3 (da) Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof
WO2005072126A3 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2008067056A3 (en) Method of inhibiting coagulation with human anti-factor va antibodies and use thereof
JP2003286300A5 (de)
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties